Trial

Tumor type

Treatment arm

PFS

ORR

OS

Months (95% CI)

HR (95% CI)

% (95% CI)

OR (95% CI)

Months (95% CI)

HR (95% CI)

Andrew Tutt [14]

Advanced breast cancer

400 mg bid

5.7 (4.6 - 7.4)

0.45 (0.23 - 0.87)b

41% (25 - 59)

NA

NA

NA

100 mg bid

3.8 (1.9 - 5.5)

22% (11 - 41)

NA

NA

NA

M. William Audeh [13]

Ovarian cancer

400 mg bid

5.8 (2.8 - 10.6)

0.47 (0.27 - 0.81)b

33% (20 - 51)

NA

NA

NA

100 mg bid

1.9 (1.8 - 3.6)

13% (4 - 31)

NA

NA

NA

Karen A. Gelmon [18]

Breast cancera

400 mg bid

Data closed

Data closed

Data closed

Data closed

Data closed

Data closed

Ovarian cancer

400 mg bid

7.3 (3.7 - 9.1)

NA

29% (19 - 41)

NA

NA

NA

Stan B. Kaye [19]

Recurrent ovarian cancer

200 mg bid

6.5 (5.5 - 10.1)

0.91 (0.48 - 1.74)

25%

1.90 (0.55 - 7.01)

9/32c

0.66 (0.27 - 1.55)

400 mg bid

8.8 (5.4 - 9.2)

0.86 (0.45 - 1.62)

31%

2.69 (0.81 - 9.76)

11/32c

1.01 (0.44 - 2.27)

PLD 50 mg/m2

7.1 (3.7 - 10.7)

18%

2.27 (1.13 - 4.79)

13/33c

Jonathan Ledermann [12] [23]

Recurrent ovarian cancer

400 mg bid

8.4 (7.4 - 11.5)

0.35 (0.25 - 0.49)

12%

3.36 (0.75 - 23.72)

29.8 (27.2 - 35.7)d

0.88 (0.64 - 1.21)

Placebo

4.8 (4.0 - 5.5)

4%

27.8 (24.4 - 34.0)

Bella Kaufman [20]

Advanced breast cancer

400 mg bid

3.7

NA

12.9% (5.7 - 23.9)

NA

11.0

NA

Advanced ovarian cancer

400 mg bid

7.0

NA

31.1% (24.6 - 38.1)

NA

16.6

NA